Sentürk, B.Dursun, H.Çöllüoglu, T.Özdamar, H.Ekin, T.Tanriverdi, Z.Kaya, D.2024-09-292024-09-2920212149-2263https://doi.org/10.5152/AnatolJCardiol.2021.37670https://search.trdizin.gov.tr/tr/yayin/detay/510201https://hdl.handle.net/20.500.14619/8863Objective: The long-term durability of transcatheter aortic bioprosthetic valves continues to be a major concern. Standardized criteria of the structural valve deterioration (SVD) and bioprosthetic valve failure (BVF) have recently been defined. Limited studies have evaluated the long-term durability of transcatheter aortic valve implantation (TAVI) according to these new definitions. We aim to analyze the durability of TAVI beyond 5 years and to report the frequency of SVD and BVF. Methods: A total of 89 patients who had undergone TAVI and had theoretically completed at least 5 years after the procedure were included. Either a Medtronic CoreValve or an Edwards SAPIEN XT valve were implanted in the patients. New standardized definitions were used to evaluate SVD and BVF. Results: The mean age of the patients was 78.70±6.95 years. SVD occured in 4 (4.5%) patients during 6 years of follow-up. Severe SVD was observed in 2 patients (2.2%), and these patients had the New York Heart Association class II symptoms. Both patients with severe SVD also met the criteria of BVF. Moderate SVD was observed in 2 patients (2.2%), and these patients had no valve-related symptoms. Of the 4 SVD cases, 2 were associated with increased mean transaortic gradients, whereas the remaining 2 cases were associated with intraprosthetic aortic regurgitation. All patients with SVD are still alive, and none of them have required aortic valve reintervention. Conclusion: Although first-generation TAVI devices were used, we determined the low rate of SVD and BVF at the 6-year follow-up. It may be suggested that there is no major concern associated with TAVI even with first-generation devices regarding long-term durability. © Copyright 2021 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.comeninfo:eu-repo/semantics/openAccessAortic valve stenosisHeart valvesTranscatheter aortic valve implantationArticle10.5152/AnatolJCardiol.2021.376702-s2.0-85111581830587834369886Q357951020125